1 completed, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Pregabalin: new trials by email Literature Review of Pregabalin trials Research Report on Pregabalin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Y-4 to Treat the Postherpetic Neuralgia Y-4 tables, Pregabalin - Postherpetic Neuralgia, Y-4 | Phase 2 | Recruiting | Neurodawn Pharmaceutical Co., Ltd. | 160 | 2026-02-02 | 2026-05-13 |
| Preemptive Analgesia Combination of Celecoxib and Pregabalin in THA Single dose of celecoxib 400 mg and pregabalin 150 mg, Repeated dose of celecoxib 200 mg and pregabalin 75 mg, Placebo - Arthroplasty Complications, Analgetic | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 30 | 2022-10-01 | 2022-08-24 |
| Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms. S-ketamine and pregabalin, Normal saline and placebo capsule - Esketamine, Pregabalin | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 90 | 2021-12-01 | 2023-07-06 |
Neuralgia, Postherpetic (1) · Pain, Postoperative (1) · Spinal Cord Neoplasms (1)
Nervous System Diseases (2) · Neurologic Manifestations (2) · Pain (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Neoplasms (1) · Neuralgia (1) · Neuromuscular Diseases (1) · Pathologic Processes (1) · Peripheral Nervous System Diseases (1) · Postoperative Complications (1)
Pregabalin (3) · Celecoxib (1) · Esketamine (1) · Saline Solution (1)
Beijing Tiantan Hospital (1) · Neurodawn Pharmaceutical Co., Ltd. (1) · Universitas Indonesia (1)
China (2)
Andri MT Lubis (1) · Ruquan Han, M.D., Ph D. (1)